Department of Dermatology, Venereology and Allergology, Ruhr-University, Bochum, Germany.
CentroDerm Clinic, Heinz-Fangman-Straße 57, Wuppertal, Germany.
Photodiagnosis Photodyn Ther. 2018 Mar;21:66-70. doi: 10.1016/j.pdpdt.2017.10.007. Epub 2017 Oct 16.
Actinic keratosis area and severity index (AKASI) is a new quantitative tool for assessing AK severity on the head and can be used to monitor outcomes of different therapies. The aim of this study was to determine treatment outcomes of AK applying AKASI three months after conventional photodynamic therapy (PDT).
We performed a retrospective analysis of patients who have undergone PDT on the head and had a documented AKASI evaluation prior to PDT and at follow-up visits.
Of the 33 patients included, 32 (97.0%) patients showed an AKASI reduction and 1 (3.0%) patient an increase of AKASI at follow-up visits compared to baseline. The median (range) follow-up period was 96days (70-161). The median difference of AKASI values between both visits was 73.7% (-34.8 to 100.0%). The Wilcoxon test showed highly significant differences (P<0.0001) between visits. 14 (42.4%) patients showed an AKASI 100 (complete clearance), 16 (48.5%) an AKASI 75 and 24 (72.7%) an AKASI 50, respectively. The Mann-Whitney U test showed in a subgroup analysis of patients with a positive history of at least more than one intervention and treatment naïve patients significant differences in these two groups (P=0.0302).
AKASI represents a feasible and comparable tool for objectively assessing field-directed treatment modalities such as PDT in daily routine. The establishment of AKASI 50, 75, 100 serves as an objective measure to compare treatment outcomes to baseline severity of AK.
光化性角化病面积和严重程度指数(AKASI)是一种新的评估头部 AK 严重程度的定量工具,可用于监测不同治疗方法的结果。本研究的目的是确定应用 AKASI 在传统光动力疗法(PDT)后三个月评估 AK 的治疗结果。
我们对接受 PDT 治疗头部的患者进行了回顾性分析,并在 PDT 前和随访时进行了 AKASI 评估。
在 33 名纳入的患者中,与基线相比,32 名(97.0%)患者在随访时 AKASI 降低,1 名(3.0%)患者 AKASI 增加。中位(范围)随访时间为 96 天(70-161)。两次就诊之间 AKASI 值的中位数差异为 73.7%(-34.8 至 100.0%)。Wilcoxon 检验显示两次就诊之间差异具有高度统计学意义(P<0.0001)。14 名(42.4%)患者 AKASI 为 100(完全清除),16 名(48.5%)患者 AKASI 为 75,24 名(72.7%)患者 AKASI 为 50。在有至少一次以上干预阳性史和无治疗史患者的亚组分析中,Mann-Whitney U 检验显示这两组之间存在显著差异(P=0.0302)。
AKASI 代表了一种可行且可比的工具,可用于客观评估 PDT 等针对病灶的治疗方法。AKASI 50、75、100 的建立可作为与 AK 基线严重程度相比比较治疗结果的客观指标。